戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  the placebo group (one CMV; one EBV-related posttransplant lymphoproliferative disorder).
2 ft nephropathy or viral infection, including posttransplant lymphoproliferative disorder.
3 r virus (EBV)-associated disorders including posttransplant lymphoproliferative disorder.
4 cytochemistry findings are consistent with a posttransplant lymphoproliferative disorder.
5  antibody-mediated rejection, infection, and posttransplant lymphoproliferative disorder.
6 imary mediastinal B-cell, and 1 CR of 3 with posttransplant lymphoproliferative disorder.
7 plant overall, skin, solid malignancies, and posttransplant lymphoproliferative disorder.
8 nts, who also experience higher incidence of posttransplant lymphoproliferative disorder.
9 mphomas, including Burkitt lymphoma (BL) and posttransplant lymphoproliferative disorder.
10 anagement of serious EBV diseases, including posttransplant lymphoproliferative disorder.
11  with multiple human malignancies, including posttransplant lymphoproliferative disorder.
12  no evidence of cytomegalovirus infection or posttransplant lymphoproliferative disorder.
13  development of graft-versus-host disease or posttransplant lymphoproliferative disorder.
14 on, such as chronic active EBV infection and posttransplant lymphoproliferative disorders.
15 have a 45% rate of progression to late-onset posttransplant lymphoproliferative disorders.
16 pleen were also introduced to reduce risk of posttransplant lymphoproliferative disorders.
17 induced by human immunodeficiency virus, and posttransplant lymphoproliferative disorders.
18 decreased IRF-1 expression in cases of human posttransplant lymphoproliferative disorder, a malignant
19  is associated with B cell proliferation and posttransplant lymphoproliferative disorder after alloge
20 d four children in group II (7.8%) developed posttransplant lymphoproliferative disorder after conver
21                      One recipient died from posttransplant lymphoproliferative disorder and another
22 ectrum of EBV latent gene expression in most posttransplant lymphoproliferative disorders and from th
23 ession, and there was no association between posttransplant lymphoproliferative disorders and pretran
24 tt's lymphoma (BL), HIV-associated lymphoma, posttransplant lymphoproliferative disorder, and nasopha
25 ell, immunoblastic large B cell, follicular, posttransplant lymphoproliferative disorder, and periphe
26 Risk of transplant pancreatic insufficiency, posttransplant lymphoproliferative disorder, and postspl
27 notherapy, for example, renal impairment and posttransplant lymphoproliferative disorder, and the eff
28            All of the children who developed posttransplant lymphoproliferative disorder are alive an
29                                              Posttransplant lymphoproliferative disorders are general
30                                              Posttransplant lymphoproliferative disorders are typical
31                            Like Wp-BL cells, posttransplant lymphoproliferative disorder cells depend
32 rr virus- (EBV) related disorders, including posttransplant lymphoproliferative disorder, constitute
33 reased risk of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder (EBV-PTLD) i
34 .2% at 12 months, and 99.1% of patients were posttransplant lymphoproliferative disorder-free through
35 n of other complications post-ITx, including posttransplant lymphoproliferative disorder, graft-versu
36 ipients were alive with no single example of posttransplant lymphoproliferative disorder, graft-versu
37              Twenty percent of patients with posttransplant lymphoproliferative disorder had a comple
38 rus (EBV) DNAemia is a major risk factor for posttransplant lymphoproliferative disorder; however, im
39                       After the diagnosis of posttransplant lymphoproliferative disorder, immunosuppr
40 iferative disorder was 10%; the incidence of posttransplant lymphoproliferative disorder in the last
41                                There were no posttransplant lymphoproliferative disorder in the thymo
42           The risk of complications, such as posttransplant lymphoproliferative disorders, in high vi
43 iver failure (n=2), chronic rejection (n=3), posttransplant lymphoproliferative disorder (n=1), graft
44  deaths occurred from de novo cancer (n=13), posttransplant lymphoproliferative disorder (n=5), age-r
45                      Anemia, neutropenia and posttransplant lymphoproliferative disorder occurred mor
46 rvival and improved QALYs, without increased posttransplant lymphoproliferative disorder or cytomegal
47 urs in the context of immunosuppression (eg, posttransplant lymphoproliferative disorders or HIV [AID
48 on of the monoclonal clone or development of posttransplant lymphoproliferative disorders or other ma
49  [OR], 0.53; P <.001) but with the increased posttransplant lymphoproliferative disorder (OR, 1.75; P
50 s C virus or hepatitis B virus, disseminated posttransplant lymphoproliferative disorder, or late rej
51 wo reported cases of cyclosporine-associated posttransplant lymphoproliferative disorders presenting
52  outcome of Epstein-Barr virus (EBV)-related posttransplant lymphoproliferative disorder (PTLD) after
53                                Occurrence of posttransplant lymphoproliferative disorder (PTLD) after
54                                              Posttransplant lymphoproliferative disorder (PTLD) and B
55 or to mortality, including two patients with posttransplant lymphoproliferative disorder (PTLD) and o
56                 Patients at greatest risk of posttransplant lymphoproliferative disorder (PTLD) are t
57  There were no new safety signals and no new posttransplant lymphoproliferative disorder (PTLD) cases
58                                              Posttransplant lymphoproliferative disorder (PTLD) conti
59 rus (EBV) and associated with development of posttransplant lymphoproliferative disorder (PTLD) follo
60                                              Posttransplant lymphoproliferative disorder (PTLD) has b
61                                              Posttransplant lymphoproliferative disorder (PTLD) has b
62                                        Human posttransplant lymphoproliferative disorder (PTLD) has b
63             The incidence of malignancies or posttransplant lymphoproliferative disorder (PTLD) in pl
64                                              Posttransplant lymphoproliferative disorder (PTLD) is a
65                                              Posttransplant lymphoproliferative disorder (PTLD) is a
66                                              Posttransplant lymphoproliferative disorder (PTLD) is a
67                                              Posttransplant lymphoproliferative disorder (PTLD) is a
68                                              Posttransplant lymphoproliferative disorder (PTLD) is a
69                                              Posttransplant lymphoproliferative disorder (PTLD) is a
70                                              Posttransplant lymphoproliferative disorder (PTLD) is a
71                                              Posttransplant lymphoproliferative disorder (PTLD) is a
72                                              Posttransplant lymphoproliferative disorder (PTLD) is a
73                                              Posttransplant lymphoproliferative disorder (PTLD) is a
74                                              Posttransplant lymphoproliferative disorder (PTLD) is an
75                                              Posttransplant lymphoproliferative disorder (PTLD) is an
76                                              Posttransplant lymphoproliferative disorder (PTLD) is an
77                                              Posttransplant lymphoproliferative disorder (PTLD) is an
78                                              Posttransplant lymphoproliferative disorder (PTLD) is on
79                          Higher incidence of posttransplant lymphoproliferative disorder (PTLD) is re
80         Recommended first-line treatment for posttransplant lymphoproliferative disorder (PTLD) is re
81 nosis of Epstein-Barr virus (EBV)-associated posttransplant lymphoproliferative disorder (PTLD) is re
82 on of immunosuppressive regimens (ISRs) with posttransplant lymphoproliferative disorder (PTLD) may b
83                                              Posttransplant lymphoproliferative disorder (PTLD) poses
84          Epstein-Barr virus (EBV)-associated posttransplant lymphoproliferative disorder (PTLD) remai
85                                              Posttransplant lymphoproliferative disorder (PTLD) repre
86            Epstein-Barr virus (EBV)-positive posttransplant lymphoproliferative disorder (PTLD) resul
87 ncidence of early Epstein-Barr virus-related posttransplant lymphoproliferative disorder (PTLD) was 9
88                         Although the rate of posttransplant lymphoproliferative disorder (PTLD) was n
89                      There were two cases of posttransplant lymphoproliferative disorder (PTLD) with
90 pressants has raised the question of whether posttransplant lymphoproliferative disorder (PTLD), a co
91                                              Posttransplant lymphoproliferative disorder (PTLD), a co
92                     One kidney failed due to posttransplant lymphoproliferative disorder (PTLD), anot
93 children; in addition, 10 children developed posttransplant lymphoproliferative disorder (PTLD), whic
94                                              Posttransplant lymphoproliferative disorder (PTLD)--spec
95 , diffuse large B-cell lymphoma (DLBCL), and posttransplant lymphoproliferative disorder (PTLD).
96 transplantation-associated, monoclonal, EBV+ posttransplant lymphoproliferative disorder (PTLD).
97                        One child died from a posttransplant lymphoproliferative disorder (PTLD).
98 transplant recipients at risk for developing posttransplant lymphoproliferative disorder (PTLD).
99  viremia through infectious mononucleosis to posttransplant lymphoproliferative disorder (PTLD).
100 homa is a rare subtype of monomorphic B-cell posttransplant lymphoproliferative disorder (PTLD).
101 ost important risk factor for development of posttransplant lymphoproliferative disorder (PTLD).
102 e recently included in the classification of posttransplant lymphoproliferative disorder (PTLD).
103 as been associated with an increased risk of posttransplant lymphoproliferative disorder (PTLD).
104 an transplant recipients with EBV-associated posttransplant lymphoproliferative disorder (PTLD).
105 lassified into skin cancer, solid tumor, and posttransplant lymphoproliferative disorder (PTLD).
106 plicating withdrawal of immunosuppression in posttransplant lymphoproliferative disorder (PTLD).
107 ype of cancer with the highest incidence was posttransplant lymphoproliferative disorder (PTLD, 1.58%
108 se The Sequential Treatment of CD20-Positive Posttransplant Lymphoproliferative Disorder (PTLD-1) tri
109 10 to 406), non-Hodgkin's lymphoma including posttransplant lymphoproliferative disorder (PTLD; SIR =
110              Epstein-Barr virus (EBV)-driven posttransplant lymphoproliferative disorders (PTLD) affe
111              The syndromes of EBV-associated posttransplant lymphoproliferative disorders (PTLD) and
112           In addition to a 0.4% incidence of posttransplant lymphoproliferative disorders (PTLD) and
113                                              Posttransplant lymphoproliferative disorders (PTLD) are
114                                              Posttransplant lymphoproliferative disorders (PTLD) are
115                                              Posttransplant lymphoproliferative disorders (PTLD) deve
116 gic differences between patients who develop posttransplant lymphoproliferative disorders (PTLD) earl
117 y was not associated with increased risk for posttransplant lymphoproliferative disorders (PTLD) in l
118                  We previously reported that posttransplant lymphoproliferative disorders (PTLD) occu
119                                              Posttransplant lymphoproliferative disorders (PTLD) stil
120 oreticular malignancies, collectively called posttransplant lymphoproliferative disorders (PTLD), eve
121 xamine the incidence of and risk factors for posttransplant lymphoproliferative disorders (PTLD).
122  children and is associated with the risk of posttransplant lymphoproliferative disorders (PTLD).
123  prior solid organ transplantation (SOT) and posttransplant lymphoproliferative disorders (PTLD).
124 mals with prolonged graft survival developed posttransplant lymphoproliferative disorders (PTLD).
125  was plagued with high risk of rejection and posttransplant lymphoproliferative disorders (PTLD).
126 tion (BMT) is linked to an increased risk of posttransplant lymphoproliferative disorders (PTLD); how
127     The genetic mechanisms that give rise to posttransplant lymphoproliferative disorders (PTLDs) are
128                                              Posttransplant lymphoproliferative disorders (PTLDs) are
129                                              Posttransplant lymphoproliferative disorders (PTLDs) are
130                                              Posttransplant lymphoproliferative disorders (PTLDs) are
131                                              Posttransplant lymphoproliferative disorders (PTLDs) enc
132 of lymphomas, but knowledge of their role in posttransplant lymphoproliferative disorders (PTLDs) is
133                                              Posttransplant lymphoproliferative disorders (PTLDs) rep
134                                              Posttransplant lymphoproliferative disorders (PTLDs) rep
135                                              Posttransplant lymphoproliferative disorders (PTLDs) tha
136 munosuppressive agents foster development of posttransplant lymphoproliferative disorders (PTLDs), th
137  expressed in the majority of EBV-associated posttransplant lymphoproliferative disorders (PTLDs).
138 is also a known factor in the development of posttransplant lymphoproliferative disorder (PTLPD) in a
139  inhibitors (tacrolimus or cyclosporine) and posttransplant lymphoproliferative disorders related to
140                                 Although the posttransplant lymphoproliferative disorder remained in
141                                              Posttransplant lymphoproliferative disorder remains an i
142                      Four patients died from posttransplant lymphoproliferative disorder, severe ACR,
143                            Recent studies on posttransplant lymphoproliferative disorders should resu
144                                   All T-cell posttransplant lymphoproliferative disorders (T-PTLDs) s
145                               In the case of posttransplant lymphoproliferative disorder, the EBV DNA
146 cytomegalovirus disease was 13%, and that of posttransplant lymphoproliferative disorder was 10%; the
147                                              Posttransplant lymphoproliferative disorder was diagnose
148 skin, solid posttransplant malignancies, and posttransplant lymphoproliferative disorder were 3.2 (1.
149                                  No cases of posttransplant lymphoproliferative disorder were seen in
150                                           No posttransplant lymphoproliferative disorders were seen i
151 omes, including opportunistic infections and posttransplant lymphoproliferative disorder, were studie
152 ugh plasma cell neoplasms are a rare form of posttransplant lymphoproliferative disorder, which could
153  recipient who developed relapsed/refractory posttransplant lymphoproliferative disorder with CD19-di
154                   Two patients who developed posttransplant lymphoproliferative disorder with plasmac

 
Page Top